ANALISIS KADAR NEUROPEPTIDA Y TERHADAP PERUBAHAN BERAT BADAN PADA PASIEN BANGKITAN EPILEPTIK ANAK PENGGUNA MONOTERAPI ASAM VALPROAT (Penelitian dilakukan di Instalasi Rawat Jalan Ilmu Penyakit Saraf dan Ilmu Kesehatan Anak RS Universitas Airlangga Surabaya dan RSUD Ngudi Waluyo Wlingi Blitar)
| Main Author: | FARAH MEDINA, 051715153026 |
|---|---|
| Format: | Thesis NonPeerReviewed Book |
| Bahasa: | ind |
| Terbitan: |
, 2019
|
| Subjects: | |
| Online Access: |
http://repository.unair.ac.id/86427/1/TFK.%2014-19%20Med%20a%20ABSTRAK.pdf http://repository.unair.ac.id/86427/2/TFK.%2014-19%20Med%20a%20DAFTAR%20ISI.pdf http://repository.unair.ac.id/86427/3/TFK.%2014-19%20Med%20a%20DAFTAR%20PUSTAKA.pdf http://repository.unair.ac.id/86427/4/TFK.%2014-19%20Med%20a.pdf http://repository.unair.ac.id/86427/ http://lib.unair.ac.id |
Daftar Isi:
- Background: Weight gain is a common side effect of valproic acid treatment. The potential mechanisms of valproate-associated weight gain in children are still unclear. Increased NPY levels are one of the possible mechanism. Objective: The aim of this study was to analyze the correlation between NPY levels and weight changes in epileptic patient taking valproic acid monotherapy. Method: A prospective observational design was conducted in this study. Blood samples were obtained two times (at first visit and a month after) from patients who visit Pediatric and Neurology Outpatient Unit from April to June 2019. NPY levels were assessed by using ELISA. The correlation between NPY levels and weight changes were analyzed using pearson test as it was on parametric data. Results: 17 patients were included in this study. There was a significant correlation between increase in level of Neuropeptide Y with increase in body weight (p = 0,03, r = 0,673). Using paired t-test analysis, there were significant differences weight at first visit with a month after (p = 0.034) , but no significant correlation was found in NPY levels (p = 0.644). Conclusion: These results suggest that weight gain during VPA treatment may be related to increases in Neuropeptide Y levels.